

**Sample Name:** NAD+ 500mg  
**Lot#:** NADH225  
**Report Date:** 9/11/2025  
**Test:** Purity

**Receipt Date:** 9/8/2025  
**Analysis Date:** 9/9/2025  
**Matrix:** Powder  
**Number of samples:** 1


## Certificate of Analysis

**Purity: 99.99%\***

\*purity does not account for the bulking agents/excipients (i.e. Mannitol)

<b>Data File</b>	20250909_MS2_pogneg_NAD+_LotNADH225_purity.d	<b>Sample Name</b>	NAD+_LotNADH225_purity
<b>Sample Type</b>	Sample	<b>Position</b>	P1 F4
<b>Instrument Name</b>	Instrument 1	<b>User Name</b>	
<b>Acq Method</b>	PuritydefaultMS2_6420a.m	<b>Acquired Time</b>	9/9/2025 5:03:39 PM (UTC-07:00)
<b>IRM Calibration Status</b>	Not Applicable	<b>DA Method</b>	20250902_S1_S1IsotopeD3_longcol_6420a.m
<b>Comment</b>		<b>Info.</b>	
<b>Sample Group</b>		<b>Acquisition Time (Local)</b>	9/9/2025 5:03:39 PM (UTC-07:00)
<b>Stream Name</b>	LC 1		
<b>Acquisition SW Version</b>	6400 Series Triple Quadrupole B.09.00 (B9037.0)		

### Chromatograms



### Peak List

Time	Area	%Area
1.981 min.	43867.25	99.99%
4.088 min.	5.02	0.01%

Reviewed and Approved By:

*Herman Lelie*

Herman Lelie Ph.D Director of R&D

Constitution Labs (CL) maintains liability limited to cost of analysis. Interpretation and use of test results are the responsibility of the client. This report relates only to the samples reported above, and may not be reproduced, except in full, without written approval by CL. This is not intended as an endorsement of any product. CL bears no responsibility for sample collection activities or analytical method limitations. Samples are within quality control criteria and met method specifications unless otherwise noted.